Biocon added 1.16% to Rs 280.05 after Biocon Biologics announced the signing of a settlement agreement with Bayer and Regeneron Pharma for introduction of Yesafili, a proposed biosimilar to EYLEA (aflibercept) injection, into the Canadian market.
| Subscribe To Our Free Newsletter |
